Neumora Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.35, missing the estimate of USD -0.3334.

EBIT: As of FY2025 Q3, the actual value is USD -58.64 M.

Financial Metrics Summary

Cash Position

• As of September 30, 2025, Neumora Therapeutics had cash, cash equivalents, and marketable securities totaling $171.5 million.

Research and Development (R&D) Expenses

• R&D expenses for the third quarter of 2025 were $40.5 million, a decrease from $60.6 million in the same period of 2024. This reduction was primarily due to the expiration of research and collaboration agreements with Amgen and a decrease in clinical trial costs.

General and Administrative (G&A) Expenses

• G&A expenses for the third quarter of 2025 were $12.2 million, down from $16.0 million in the same period of 2024, mainly due to lower consulting and personnel-related costs.

Net Loss

• The net loss for the third quarter of 2025 was $56.8 million, compared to a net loss of $72.5 million for the same period in 2024.

Financial Guidance

• The company expects its cash, cash equivalents, and marketable securities as of September 30, 2025, to fund its operating plan into 2027.

Outlook / Guidance

• Neumora plans to initiate a clinical program with NMRA-215 in the first quarter of 2026, with human proof of concept data expected later that year. The company is also on track to report data from a Phase 1b study of NMRA-511 in Alzheimer’s disease agitation around the end of 2025. Additionally, topline data from the Phase 3 KOASTAL program for navacaprant in major depressive disorder is expected in the first half of 2026.